These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33485811)

  • 1. Incidence and dosimetric predictive factors of late rectal toxicity after low-dose-rate brachytherapy combined with volumetric modulated arc therapy in high-risk prostate cancer at a single institution: Retrospective study.
    Sakurai T; Takamatsu S; Shibata S; Taka M; Ishiyama M; Yamazaki M; Kojima H; Mizokami A; Kumano T; Gabata T
    Brachytherapy; 2021; 20(3):584-594. PubMed ID: 33485811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors of rectal hemorrhage in patients with localized prostate cancer who underwent low-dose-rate brachytherapy.
    Taniguchi T; Iinuma K; Kato D; Takai M; Maekawa YM; Nakane K; Mizutani K; Tsuchiya T; Nakano M; Kato T; Ito M; Kumano T; Matsuo M; Koie T
    Int J Clin Oncol; 2020 Sep; 25(9):1711-1717. PubMed ID: 32500469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients.
    Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
    Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
    Yang R; Zhao N; Liao A; Wang H; Qu A
    Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
    Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
    Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
    Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
    Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
    Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
    Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dosimetric comparison of Volumetric Modulated Arc Therapy (VMAT) and High Dose Rate (HDR) brachytherapy in localized cervical cancer radiotherapy.
    Wali L; Helal A; Darwesh R; Attar M
    J Xray Sci Technol; 2019; 27(3):473-483. PubMed ID: 30958322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
    Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy.
    Nakai Y; Tanaka N; Asakawa I; Morizawa Y; Yamaki K; Hori S; Gotoh D; Miyake M; Torimoto K; Hasegawa M; Fujimoto K
    Brachytherapy; 2022; 21(5):626-634. PubMed ID: 35644732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: With or without supplemental external beam radiotherapy.
    Serrano N; Moghanaki D; Asher D; Karlin J; Schutzer M; Chang M; Hagan MP
    Brachytherapy; 2016; 15(4):435-441. PubMed ID: 27180124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion.
    Zhang H; Wang L; Riegel AC; Antone J; Potters L; Lee L; Cao Y
    J Appl Clin Med Phys; 2022 Jun; 23(6):e13584. PubMed ID: 35285578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectal dose constraints for salvage iodine-125 prostate brachytherapy.
    Peters M; Hoekstra CJ; van der Voort van Zyp JR; Westendorp H; van de Pol SM; Moerland MA; Maenhout M; Kattevilder R; van Vulpen M
    Brachytherapy; 2016; 15(1):85-93. PubMed ID: 26614233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
    Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
    Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.